Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis

Michael E. Hettinger, Deborah Pavan Langston, Hee Park, Daniel Albert, Erik Clercq, Tai Shun Lin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The therapeutic efficacy of three new antiviral agents—5-iodo-3',5'-diacetyl-2-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside—is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1% Ac2 IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.

Original languageEnglish (US)
Pages (from-to)1618-1621
Number of pages4
JournalArchives of ophthalmology
Volume99
Issue number9
DOIs
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Investigational Therapies
Keratitis
Iritis
Corneal Ulcer
Placebos
Human Herpesvirus 1
Antiviral Agents
Herpetic Keratitis
Diacetyl
Deoxyuridine
Thymine
Theoretical Models
Rabbits
Viruses
ara-T
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis. / Hettinger, Michael E.; Pavan Langston, Deborah; Park, Hee; Albert, Daniel; Clercq, Erik; Lin, Tai Shun.

In: Archives of ophthalmology, Vol. 99, No. 9, 01.01.1981, p. 1618-1621.

Research output: Contribution to journalArticle

Hettinger, Michael E. ; Pavan Langston, Deborah ; Park, Hee ; Albert, Daniel ; Clercq, Erik ; Lin, Tai Shun. / Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis. In: Archives of ophthalmology. 1981 ; Vol. 99, No. 9. pp. 1618-1621.
@article{2cfd2fcb88db42679e05ee59ab425928,
title = "Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis",
abstract = "The therapeutic efficacy of three new antiviral agents—5-iodo-3',5'-diacetyl-2-deoxyuridine (diacetylidoxuridine, 1{\%} Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25{\%} BVDU), and 3{\%} thymine arabinoside—is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1{\%} Ac2 IDU and 0.25{\%} BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.",
author = "Hettinger, {Michael E.} and {Pavan Langston}, Deborah and Hee Park and Daniel Albert and Erik Clercq and Lin, {Tai Shun}",
year = "1981",
month = "1",
day = "1",
doi = "10.1001/archopht.1981.03930020492020",
language = "English (US)",
volume = "99",
pages = "1618--1621",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis

AU - Hettinger, Michael E.

AU - Pavan Langston, Deborah

AU - Park, Hee

AU - Albert, Daniel

AU - Clercq, Erik

AU - Lin, Tai Shun

PY - 1981/1/1

Y1 - 1981/1/1

N2 - The therapeutic efficacy of three new antiviral agents—5-iodo-3',5'-diacetyl-2-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside—is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1% Ac2 IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.

AB - The therapeutic efficacy of three new antiviral agents—5-iodo-3',5'-diacetyl-2-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside—is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1% Ac2 IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.

UR - http://www.scopus.com/inward/record.url?scp=0019390265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019390265&partnerID=8YFLogxK

U2 - 10.1001/archopht.1981.03930020492020

DO - 10.1001/archopht.1981.03930020492020

M3 - Article

VL - 99

SP - 1618

EP - 1621

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -